US3830814A - N-oxides of dibenzo(b,f)thiepines - Google Patents

N-oxides of dibenzo(b,f)thiepines Download PDF

Info

Publication number
US3830814A
US3830814A US00096262A US9626270A US3830814A US 3830814 A US3830814 A US 3830814A US 00096262 A US00096262 A US 00096262A US 9626270 A US9626270 A US 9626270A US 3830814 A US3830814 A US 3830814A
Authority
US
United States
Prior art keywords
thiepine
dihydrodibenzo
ethanol
methylpiperazino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00096262A
Inventor
J Jilek
M Protiva
J Metysova
J Pomykacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spofa Vereinigte Pharma Werke
Original Assignee
Spofa Vereinigte Pharma Werke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spofa Vereinigte Pharma Werke filed Critical Spofa Vereinigte Pharma Werke
Application granted granted Critical
Publication of US3830814A publication Critical patent/US3830814A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/14—[b,f]-condensed

Definitions

  • the known psychotropic preparations such as chlorpromazine which is chemically 2-chloro-10-(3-dimethylaminopropyl)-phenothiazine exhibit a high tranquilizing activity along with the cataleptic action.
  • chlorpromazine which is chemically 2-chloro-10-(3-dimethylaminopropyl)-phenothiazine exhibit a high tranquilizing activity along with the cataleptic action.
  • this invention relates to a new series of N-oxides of dibenzo[b,f]thiepines and the salts thereof, as well as the production of these compounds, these compounds exhibiting a relatively high cataleptic activity with relatively no tranquilizing action.
  • the present invention mainly comprises new N-oxides of dibenzo ([b,f]thiepines of Formula I below:
  • R is selected from the group consisting of hydrogen, halogen, trifiuoromethy], alkyl of l-4 carbon atoms, alkoxy of 1-4 carbon atoms and alkylthio of 1-4 carbon atoms,
  • R is selected from the group consisting of alkyl of 1-4 carbon atoms and hydroxy alkyl of 2-4 carbon atoms, and
  • X is selected from the group consisting of sulfur, SO and S0
  • the present invention also relates to salts of the above compounds, particularly salts with nontoxic, physiologically compatible inorganic and organic compounds.
  • the above compounds exhibit a marked tranquilizing and psychotropic activity so that the same can be used ice as agents in the treatment of mental and nervous dis orders.
  • the compounds of the present invention are produced by reacting the basic tertiary amine of the following Formula II:
  • the carrying out of the method is extremely simple.
  • the oxidation reaction proceeds even at room temperature and the reaction is ended by heating to the boiling temperature of the reaction mixture.
  • the obtained basic product exhibits, contrary to the starting tertiary amine, a marked hydrophilic characteristic and it crystallizes preponderantly in the form of the hydrate.
  • the salts which are obtained by neutralization with inorganic or organic acids can be used to make preparations for different forms of administration.
  • EXAMPLE 1 6.6 g. of 25% hydrogen peroxide are added to a warmed solution at 10.0 g. of 10-(4-methylpiperazino)-l0,1l-dihydrodibenzo[b,f]thiepine base in 65 ml. of ethanol and the reaction mixture is permitted to stand at room temperature overnight. It is then heated for 3 hours to boiling under refluxing and an additional hour with a small platinum prism for the purpose of decomposing the excess peroxide. After filtration the filtrate is mixed with 20 ml. water and the solution evaporated under reduced pressure. The remaining crystalline mixture is diluted with 60 ml. of water and is allowed to crystallize for 12 hours.
  • the precipitated product is filtered off under suction, washed with a small amount of water and dried under vacuum over phosphorous pentoxide. There is obtained 7.4 g. (70% of the theoretical) of 10 (4 methylpiperazino)- 10,11 dihydrodibenzo[b,f]thiepine N oxide in the form of its dihydrate, which retains its water in crystallization even after recrystallization from benezene.
  • the melting point is 110-112 C.
  • After neutralization with hydrogen chloride in an ethanol-ether mixture the base is converted into the corresponding crystalline hydrochloride which crystallizes from ethanol-ether in the form of the hemihydrate and which melts at l78182 C.
  • EXAMPLE 2 2.0 ml. of 25% hydrogen peroxide are added to a solution of 3.45 g. of 8 chloro 10 (4 methylpiperazino)- 10,11 dihydrodibenzo [b,f] thiepine base in 18 ml. of 95% ethanol. The mixture is permitted to stand overnight at room temperature and it is then heated for 3 hours to boiling under refluxing, mixed with 30 ml. of water and evaporated under reduced pressure. The residue is mixed with an additional 50 ml. of water, the crystallized product is filtered 01f under suction and dried under vacuum over phosphorous pentoxide. There is obtained 3.4 g.
  • EXAMPLE 4 A solution of 3.5 g. of 8 chloro 10 [4 (3 hydroxypropyl)piperazino] 10,11 dihydrodibenzo[b,f]thiepine base in 18 ml. of 95% ethanol is oxidized with 2 ml. of 25 hydrogen peroxide in analogous manner to the preceding examples. There is obtained 2.1 g. of the pure monohydrate of 8 chloro 1O [4 (3 hydroxypropyl)- 'piperazino] 10,11 dihydrodibenzo[b,f]thiepine-N-oxide which melts at 156-159 C. (benzene). By neutralization with hydrogen chloride in ethanol the base is converted to the corresponding dihydrochloride-hemihydrate which melts at 155158 C. (ethanol).
  • R is hydrogen, halogen, alkyl of 1-4 carbon atoms, and alkoxy of 1-4 carbon atoms; R is alkyl of 1-4 carbon atoms or monohydroxy alkyl of 2 to 4 carbon atoms and their pharmaceutically acceptable acid addition salts.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

N-OXIDES OF DIBENZO(B,F)THIEPINES AND SALTS THEREOF, THESE COMPOUNDS EXHIBITING A RELATIVELY HIGH CATAAEPTIC ACITIVITY WITH A RELATIVELY LOW CENTRAL SEDATIVE OR TRANQUILIZNG ACTION. THE INVENTION FURTHER RELATES TO THE PRODUCTION OF THESE NEW COMPOUNDS.

Description

United States Patent 3,830,814 N-OXIDES 0F DIBENZO[b,f]THIEPINES Jiri Jilek, Miroslav Protiva, Jirina Metysova, and Josef Pomykacek, Prague, Czechoslovakia, assignors to SPOFA, United Pharmaceutical Works, Prague, Czechoslovakia No Drawing. Filed Dec. 8, 1970, Ser. No. 96,262 Claims priority, application Czechoslovakia, Dec. 10, 1969, 8,111/69 Int. Cl. C07d 51/70 US. Cl. 260-268 TR 4 Claims ABSTRACT OF THE DISCLOSURE N-oxides of dibenzo[b,f]thiepines and salts thereof, these compounds exhibiting a relatively high cataleptic activity with a relatively low central sedative or tranquilizing action. The invention further relates to the production of these new compounds.
BACKGROUND OF THE INVENTION The known psychotropic preparations such as chlorpromazine which is chemically 2-chloro-10-(3-dimethylaminopropyl)-phenothiazine exhibit a high tranquilizing activity along with the cataleptic action. For the treatment of psychotic conditions of the schizophrenia type it is desirable to provide a cataleptic effect without a high degree of tranquilizing action. It is as to this problem that the present invention is directed.
SUMMARY OF THE INVENTION Generally speaking this invention relates to a new series of N-oxides of dibenzo[b,f]thiepines and the salts thereof, as well as the production of these compounds, these compounds exhibiting a relatively high cataleptic activity with relatively no tranquilizing action.
It is a primary object of the present invention to provide these new compounds and also to provide for the production of the same.
It is a further object of the present invention to provide such compounds with a high degree of cataleptic activity and a relatively low tranquilizing activity.
Other objects and advantages of the present invention would be apparent from a further reading of the specification and of the appended claims.
With the above and other objects in view, the present invention mainly comprises new N-oxides of dibenzo ([b,f]thiepines of Formula I below:
wherein R is selected from the group consisting of hydrogen, halogen, trifiuoromethy], alkyl of l-4 carbon atoms, alkoxy of 1-4 carbon atoms and alkylthio of 1-4 carbon atoms,
wherein R is selected from the group consisting of alkyl of 1-4 carbon atoms and hydroxy alkyl of 2-4 carbon atoms, and
wherein X is selected from the group consisting of sulfur, SO and S0 The present invention also relates to salts of the above compounds, particularly salts with nontoxic, physiologically compatible inorganic and organic compounds.
The above compounds exhibit a marked tranquilizing and psychotropic activity so that the same can be used ice as agents in the treatment of mental and nervous dis orders.
In the case of the compounds of the present invention it has been found that in comparison to the analogous tertiary amines the displacement of the equilibrium tranquilizing-cataleptic activity in favor of the cataleptic activity occurs, which from the standpoint of use is a particularly favorable characteristic in the treatment of psychotic conditions of the schizophrenia type.
Thus, for example, in the case of 8-chloro-10-[4-(3- hydroxypropyl)piperazino] 10,11 dihydrodibenzo[b,f] thiepine-N-oxide-dihydrochloride, the production of which is described in Example 4 it is found in the rotating rod test on mice (which is utilized as the criterion for cen tral sedative or tranquilizing activity) upon intravenous administration the average active dose ED is 2.1 mg./ kg, and in the catalepsis test on rats upon intraperitoneal administration is 2.0 mg./kg. The known neuroleptic preparation Chlorpromazine" in the same tests shows an ED value in the first test (tranquilizing) of 0.6 mg./ kg. and in the second test (cataleptic) of 8.6 mg./kg. Thus, while the compound of the present invention exhibits about one-fourth the tranquilizing activity of chlorpromazine, it is four times as active as the chlorpromazine in the cataleptic test. This disproportion of the two actions is even more markedly noticeable upon comparison of the compound of the present invention with Octoclothepin, that is with 8-chloro-10 (4-methylpiperazino)- 10,11-dihydrodibenzo [b,f]thiepine. The ED value of this substance in the above two tests is 0.06 mg./kg. for the tranquilizing test and 2.4 mg./kg. for the cataleptic test. It is apparent from these results that while exhibiting practically the same cataleptic activity, the new compound of the present invention has about ,6 the tranquilizing activity.
The compounds of the present invention are produced by reacting the basic tertiary amine of the following Formula II:
(II) X wherein R R and X have the same definitions as in Formula I, with hydrogen peroxide in an equivalent amount up to a -25% excess. The oxidation reaction is preferably carried out in ethanol, and the obtained base may be converted into the corresponding salt by reaction with the selected inorganic or organic acid.
The carrying out of the method is extremely simple. The oxidation reaction proceeds even at room temperature and the reaction is ended by heating to the boiling temperature of the reaction mixture. The obtained basic product exhibits, contrary to the starting tertiary amine, a marked hydrophilic characteristic and it crystallizes preponderantly in the form of the hydrate. The salts which are obtained by neutralization with inorganic or organic acids can be used to make preparations for different forms of administration.
DESCRIPTION OF PREFERRED EMBODIMENTS The invention is further illustrated in the following examples. The scope of the invention is not, however, meant to be limited to the specific details of the examples.
EXAMPLE 1 6.6 g. of 25% hydrogen peroxide are added to a warmed solution at 10.0 g. of 10-(4-methylpiperazino)-l0,1l-dihydrodibenzo[b,f]thiepine base in 65 ml. of ethanol and the reaction mixture is permitted to stand at room temperature overnight. It is then heated for 3 hours to boiling under refluxing and an additional hour with a small platinum prism for the purpose of decomposing the excess peroxide. After filtration the filtrate is mixed with 20 ml. water and the solution evaporated under reduced pressure. The remaining crystalline mixture is diluted with 60 ml. of water and is allowed to crystallize for 12 hours. The precipitated product is filtered off under suction, washed with a small amount of water and dried under vacuum over phosphorous pentoxide. There is obtained 7.4 g. (70% of the theoretical) of 10 (4 methylpiperazino)- 10,11 dihydrodibenzo[b,f]thiepine N oxide in the form of its dihydrate, which retains its water in crystallization even after recrystallization from benezene. The melting point is 110-112 C. After neutralization with hydrogen chloride in an ethanol-ether mixture the base is converted into the corresponding crystalline hydrochloride which crystallizes from ethanol-ether in the form of the hemihydrate and which melts at l78182 C.
EXAMPLE 2 2.0 ml. of 25% hydrogen peroxide are added to a solution of 3.45 g. of 8 chloro 10 (4 methylpiperazino)- 10,11 dihydrodibenzo [b,f] thiepine base in 18 ml. of 95% ethanol. The mixture is permitted to stand overnight at room temperature and it is then heated for 3 hours to boiling under refluxing, mixed with 30 ml. of water and evaporated under reduced pressure. The residue is mixed with an additional 50 ml. of water, the crystallized product is filtered 01f under suction and dried under vacuum over phosphorous pentoxide. There is obtained 3.4 g. of 8-chloro- 10 (4 methylpiperazino) 10,11 dihydrodibenzo [b,f] thiepine N oxide in the form of the monohydrate which retains its water of crystallization even after recrystallization from acetone or benzene. The analytically pure product melts at 129-131" C. By neutralization with hydrogen chloride in ethanol the base is converted to the corresponding monohydrochloride which melts at 198200 (ethanol) EXAMPLE 3 A solution of 7.6 g. of 8 methylthio 10 (4-methylpiperazino) 10,11 dihydrodibenzo[b,f]thiepine-base in 40 ml. of 95 ethanol is oxidized by means of 3.7 m1. of 25 hydrogen peroxide in analogous manner to the preceding examples. There is obtained in practically theoretical yield the 8-methylthio 10 (4 methylpiperazino)- 10,11 dihydrodibenzo[b,f]thiepine-N-oxide in the form of a syrupy hydrate which is dissolved in ethanol and neutralized with an ethanolic hydrogen chloride solution. There is thus obtained the crystalline dihydrochloride-dihydrate of the above product which melts at 176-178 C.
and which violently decomposes at above 185 C.
EXAMPLE 4 A solution of 3.5 g. of 8 chloro 10 [4 (3 hydroxypropyl)piperazino] 10,11 dihydrodibenzo[b,f]thiepine base in 18 ml. of 95% ethanol is oxidized with 2 ml. of 25 hydrogen peroxide in analogous manner to the preceding examples. There is obtained 2.1 g. of the pure monohydrate of 8 chloro 1O [4 (3 hydroxypropyl)- 'piperazino] 10,11 dihydrodibenzo[b,f]thiepine-N-oxide which melts at 156-159 C. (benzene). By neutralization with hydrogen chloride in ethanol the base is converted to the corresponding dihydrochloride-hemihydrate which melts at 155158 C. (ethanol).
EXAMPLE 5 A solution of 4.2 g. of 8-chloro-10-(4-methylpiperazino)-10,1 1-dihydrodibenzo[b,f]thiepine-S-oxide base in 20 ml. of 95% ethanol is oxidized with 2.5 ml. of 25 hydrogen peroxide similarly to the preceding examples. By recrystallization of the crude product from 30 ml. of acetone there is obtained pure 8-chloro-l0-(4-methylpiperazino)-10,1l-dihydrodibenzo[b,f]thiepine-5,N oxide in the form of the sesquihydrate in the yield of 3.5 g. which corresponds to 75% of the theoretical, and having a melting point of l53 C. By heating above the melting point the substance again solidifies to a crystalline material and now melts at ZOO-207 C. By neutralization with hydrogen chloride in ethanol there is obtained the crystalline dihydrochloride which melts at 203207 C. (waterethanol).
EXAMPLE 6 In an analogous manner to the preceding examples a solution of 3.5 g. of 8-chloro-10-(4-methylpiperazino)- 10,11-dihydrodibenzo[b,f]thiepine-5,5-dioxide base in 30 ml. of ethanol is oxidized with 2.3 ml. of 25 hydrogen peroxide. After recrystallization of the crude product from 5 ml. of water there is obtained 2.5 g. (68% of the theoretical) of crystalline 8-chloro-10-(4-methylpiperazino)- 10,11 dihydrodibenzo[b,f]thiepine-5,5,N-trioxide-monohydrate which melts at 203-206 C. By neutralization with hydrogen chloride in ethanol the corresponding dihydrochloride is obtained which melts sharply with decomposition at 180-188" C. (water-ethanol).
While the invention has been illustrated in particular with respect to the production of certain specific compounds, it is apparent that variations and modifications of the invention can be made without departing from the spirit or scope thereof.
What is claimed is:
1. A compound of the formula wherein R is hydrogen, halogen, alkyl of 1-4 carbon atoms, and alkoxy of 1-4 carbon atoms; R is alkyl of 1-4 carbon atoms or monohydroxy alkyl of 2 to 4 carbon atoms and their pharmaceutically acceptable acid addition salts.
2. Compound according to claim 1 wherein said compound is selected from the group consisting of 10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepine N oxide, the dihydrate thereof and the dihydrochloride-hemihydrate thereof.
3. Compound according to claim 1 wherein said compound is selected from the group consisting of 8-chloro- 10 (4 methylpiperazino) 10,11 dihydrodibenzo [b,f] thiepine-N-oxide, the monohydrate thereof and the hydrochloride thereof.
4. Compound according to claim 1 wherein said compound is selected from the group consisting of 8-chloro- 10-[4-(3-hydroxypropyl)piperazino] 10,11 dihydrodibenzo [b,'f] thiepine-N-oxide, the monohydrate thereof and the dihydrochloride-hemihydrate thereof.
References Cited UNITED STATES PATENTS 3,047,579 7/ 1962 Witman 260289 R 3,337,554 8/1967 Jilek 260268 T R 3,341,533 8/1967 Yale 260268 T R 3,509,154 4/1970 Fouche 260268 T R 3,563,993 2/1971 Schindler 260268 T R 3,351,599 11/1967 Protiva 260268 T R DONALD G. DAUS, Primary Examiner US. Cl. X.R. 424-250
US00096262A 1969-12-10 1970-12-08 N-oxides of dibenzo(b,f)thiepines Expired - Lifetime US3830814A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS8111A CS148851B1 (en) 1969-12-10 1969-12-10

Publications (1)

Publication Number Publication Date
US3830814A true US3830814A (en) 1974-08-20

Family

ID=5431258

Family Applications (1)

Application Number Title Priority Date Filing Date
US00096262A Expired - Lifetime US3830814A (en) 1969-12-10 1970-12-08 N-oxides of dibenzo(b,f)thiepines

Country Status (11)

Country Link
US (1) US3830814A (en)
JP (1) JPS494463B1 (en)
AT (1) AT297714B (en)
BE (1) BE759999A (en)
CH (1) CH547307A (en)
CS (1) CS148851B1 (en)
DE (1) DE2060903B2 (en)
FR (1) FR2081339B1 (en)
GB (1) GB1277854A (en)
NL (1) NL7018025A (en)
SE (1) SE366747B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985750A (en) * 1970-07-30 1976-10-12 Spofa, Sdruzeni Podniku Pro Zdravotnickou Vyrobu Fatty acid esters of 8-substituted 10-[4-(hydroxyalkyl)piperazino]-10,11-dihydrodibenzo[b,f]thiepins
US4111261A (en) * 1977-03-14 1978-09-05 Halliburton Company Wellhead isolation tool
EP1339696A1 (en) * 2000-12-08 2003-09-03 Pfizer Products Inc. Benzyl(idene)-lactams and their use as 5ht1-receptor ligands

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56125158U (en) * 1980-02-22 1981-09-24

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985750A (en) * 1970-07-30 1976-10-12 Spofa, Sdruzeni Podniku Pro Zdravotnickou Vyrobu Fatty acid esters of 8-substituted 10-[4-(hydroxyalkyl)piperazino]-10,11-dihydrodibenzo[b,f]thiepins
US4111261A (en) * 1977-03-14 1978-09-05 Halliburton Company Wellhead isolation tool
EP1339696A1 (en) * 2000-12-08 2003-09-03 Pfizer Products Inc. Benzyl(idene)-lactams and their use as 5ht1-receptor ligands

Also Published As

Publication number Publication date
FR2081339A1 (en) 1971-12-03
CS148851B1 (en) 1973-05-24
CH547307A (en) 1974-03-29
GB1277854A (en) 1972-06-14
NL7018025A (en) 1971-06-14
SE366747B (en) 1974-05-06
AT297714B (en) 1972-04-10
BE759999A (en) 1971-05-17
FR2081339B1 (en) 1975-12-26
JPS494463B1 (en) 1974-02-01
DE2060903A1 (en) 1971-06-16
DE2060903B2 (en) 1976-07-22

Similar Documents

Publication Publication Date Title
US3310553A (en) Alkylated thioxathenesulfonamides
PL69767B1 (en) 11-substituted 5 11-dihydro-6h-pyrido(2 3-b)(1 4)benzodiazepin-6-ones [us3660380a]
EP0674627A1 (en) Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US3704245A (en) Tricyclic enol ether compounds
US3444169A (en) Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
US3928356A (en) 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
US3962248A (en) Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
US3830814A (en) N-oxides of dibenzo(b,f)thiepines
Shetty et al. Synthesis and activity of some 3-aryl-and 3-aralkyl-1, 2, 3, 4-tetrahydro-4-oxo-6-quinazolinesulfonamides
US2694705A (en) Nx c c ox a a
US3720674A (en) 4-amino-1h-pyrazolo(3,4-d)pyrimidine derivatives
GB1330966A (en) N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
US2956996A (en) Alkylated phenotfflazenecarboxamede
US3396165A (en) 9-aminomethyl-3, 8-diloweralkyl-10-hydroxy-5-oxo-1, 2, 3, 4-tetrahydrobenzopyrano [3,4-c] pyridines
US3150125A (en) 5-(basic substituted)-10, 11-dihydro-11-oxo-5h-dibenzo[b, e][1, 4]diazepine compounds
US2979502A (en) Phenthiazine derivatives
IL44489A (en) Quaternary salts of 11-(8-alkyl-3-nortropanyloxy)-6,11-dihydrodibenzo(b,e)thiepine derivatives,their production and pharmaceutical compositions containing them
DK144793B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF DIHYDRO OR TETRAHYDROIMINOTHIAZINES OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS THEREOF
US3657276A (en) Dibenzo (c f) thiazepine (1 2) compounds
US3951961A (en) Xanthene and thioxanthene derivatives, compositions thereof and a method of preparation thereof
US3632653A (en) Ethano-anthracenes
US2941999A (en) Phenthiazine derivatives
US3822267A (en) 1 substituted 4 piperazino cycloalkylthiazoles
US3370061A (en) 11-amino-10, 11-dihydro-5h-dibenzo[a, d]cyclohepten-10-ones
US3862320A (en) Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide